Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle cell disease patients with HbSS~* eGFR \<90 ml/min/1.73m2 (determined by abbreviated 4 variable modification MDRD equation) and/or measured urinary albumin to creatinine ratio \>30mg/g.~* Age ≥18 years~Exclusion Criteria:~* Previous chronic treatment with alkali (including sodium bicarbonate, calcium carbonate or baking soda)~* Bicarbonate level \>25 mEq/L~* Decompensated heart failure~* Uncontrolled systolic blood pressure \>140 mm/Hg (the cutoff for systolic hypertension in SCD is lower than in non-SCD)~* Moderate-to-severe lower extremity edema~* Projected progression to ESRD within 6 months~* Kidney transplantation~* Treatment with immunosuppressives within the last 3 months~* Vasoocclusive (VOC) within 1 week of study entry~* Active (open) leg ulcer~* Change in hydroxyurea dose within the last 3 months, unless a self-limited interruption of a stable dose~* Blood transfusion within 8 weeks, unless on chronic transfusions~* Pregnancy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Bicarbonate (Type: EXPERIMENTAL): Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:

Based on this trial design, predict the completion outcome and termination type (if applicable).